SavedAdd your journal

Journals / The Anatolian Journal of Cardiology / 2020 / Cilt: 23 - Sayı: 4

Angiotensin (1-7) and apelin co-therapy: New strategy for heart failure treatment in rats

Ava Soltani HEKMAT
Kazem JAVANMARDİ
Alireza TAVASSOLİ
Yousof GHOLAMPOUR
Pages
209–217
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Co-therapy with apelin and Ang (1–7) was more effective than either agent used alone in restoringthese parameters to that of control rats.Conclusion: The results of this study showed that the combination of apelin and Ang (1–7) had a more cardioprotective effect than either usedalone against ISO-induced heart failure, and co-therapy may be a useful treatment option for myocardial injuries and heart failure. (Anatol JCardiol 2020; 23: 209-17)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Isoproterenol (ISO)-induced heart failure is a standardized model for the study of beneficial effects of various drugs.
📊
Key Findings & Data:Both apelin andangiotensin 1–7 have a cardiac protective effect.
💡
Conclusion & Impact:Co-therapy with apelin and Ang (1–7) was more effective than either agent used alone in restoringthese parameters to that of control rats.Conclusion: The results of this study showed that the combination of apelin and Ang (1–7) had a more cardioprotective effect than either usedalone against ISO-induced heart failure, and co-therapy may be a useful treatment option for myocardial injuries and heart failure. (Anatol JCardiol 2020; 23: 209-17)
🔬Design:Modeling & Simulation
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: Isoproterenol (ISO)-induced heart failure is a standardized model for the study of beneficial effects of various drugs. Both apelin andangiotensin 1–7 have a cardiac protective effect. We assumed that co-therapy with apelin and angiotensin 1–7 [Ang (1–7)] may have synergisticcardioprotective effects against isoproterenol-induced heart failure.Methods: The rats were randomly assigned to one of eight groups, 7 animals in each, as follows: (1) Control I (saline; IP injection), (2) Control II(saline; via mini-osmotic pump), (3) ISO (5 mg/kg; IP), (4) Apelin (20 μg/kg; IP), (5) Ang (1–7) (30 μg/kg/day; via mini-osmotic pump), (6) Apelin+ISO,(7) Ang (1–7)+ISO, and (8) Apelin+Ang (1–7)+ISO. Rat myocardial injury was induced by intraperitoneal injection of 5 mg/kg of ISO for 10 days.Apelin and Ang (1–7) were administered 30 minutes before the ISO injection.Results: A decrease in the systolic blood pressure [SBP (p<0.001)], diastolic blood pressure [DBP (p=0.024)], left ventricular systolic pressure[LVSP (p<0.001)], left ventricular contractility [dP/dt max. (p<0.001)], relaxation [dP/dt min. (p<0.001)], and an increase in left ventricular enddiastolic pressure [LVEDP, (p<0.001)] were observed in ISO-treated rats. Plasma LDH and myocardial and plasma MDA were higher in the ISOheart than in controls (p<0.001). Histopathological examination of the cardiac tissue showed myocardial fibrosis and leukocyte infiltration inISO-treated rats as compared to control. Co-therapy with apelin and Ang (1–7) was more effective than either agent used alone in restoringthese parameters to that of control rats.Conclusion: The results of this study showed that the combination of apelin and Ang (1–7) had a more cardioprotective effect than either usedalone against ISO-induced heart failure, and co-therapy may be a useful treatment option for myocardial injuries and heart failure. (Anatol JCardiol 2020; 23: 209-17)

🔖

Cite This Article

HEKMAT, A. S., JAVANMARDİ, K., TAVASSOLİ, A., GHOLAMPOUR, Y. (2020). Angiotensin (1-7) and apelin co-therapy: New strategy for heart failure treatment in rats. The Anatolian Journal of Cardiology, Cilt: 23 - Sayı: 4, 209–217. https://ajindex.com/articles/365224

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Roger VL. Epidemiology of heart failure. Circ Res 2013; 113: 646– 59
  2. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 2018; 137: e67-492
  3. Krenek P, Kmecova J, Kucerova D, Bajuszova Z, Musil P, Gazova A, et al. Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function. Eur J Heart Fail 2009; 11: 140–6
  4. Loot AE, Roks AJM, Henning RH, Tio RA, Suurmeijer AJH, Boomsma F, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002; 105: 1548–50
  5. Santos RA, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs 2005; 14: 1019–31
  6. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, et al. Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Circ Physiol 2005; 289: H2356–63
  7. Wang LJ, He JG, Ma H, Cai YM, Liao XX, Zeng WT, et al. Chronic administration of angiotensin-(1-7) attenuates pressure-overload left ventricular hypertrophy and fibrosis in rats. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 481–7
  8. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251: 471–6
  9. O’Carroll AM, Selby TL, Palkovits M, Lolait SJ. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta 2000; 1492: 72–80
  10. Siddiquee K, Hampton J, McAnally D, May L, Smith L. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol 2013; 168: 1104–17
  11. Jia YX, Pan CS, Zhang J, Geng B, Zhao J, Gerns H, et al. Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept 2006; 133: 147–54
  12. Charles CJ. Update on apelin peptides as putative targets for cardiovascular drug discovery. Expert Opin Drug Discov 2011; 6: 633– 44
  13. Sato T, Suzuki T, Watan